Close menu




BAYER AG NA O.N.

Photo credits: pixabay.com

Commented by Armin Schulz on January 12th, 2022 | 13:42 CET

Bayer, XPhyto Therapeutics, MorphoSys - Which pharmaceutical companies bring returns?

  • Biotechnology

Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.

Read

Commented by Stefan Feulner on January 11th, 2022 | 11:20 CET

Steinhoff, Aspermont, Bayer - Crazy speed

  • Digitization

In terms of digitization, Germany lags light years behind other countries. Most of the big Internet success stories were written in the USA with Facebook, Google, Amazon and Apple. Yet new developments are coming faster and faster, and the digital transformation continues unabated. Down Under, the next success story is currently being built: The transformation of a venerable publishing house into a digital media company. The next big step is on the horizon, which should bring great potential for investors with the help of new shareholders. But the story is still in its infancy.

Read

Commented by Stefan Feulner on January 5th, 2022 | 11:10 CET

Avoiding penalties with Bayer, MAS Gold and BASF

  • Gold

According to the "Allianz Global Wealth Report", global financial assets have grown strongly. Private households alone had gross financial assets of over EUR 200 trillion worldwide in the past year, representing an increase of almost 10% compared to the previous year. The reason for the high savings rate was mainly the uncertainty surrounding the Corona pandemic. Now, with punitive interest rates and rising inflation, there are renewed threats to citizens' assets. One way out would be to invest in precious metals and build up long-term equity positions, primarily in the value sector.

Read

Commented by Armin Schulz on January 3rd, 2022 | 08:59 CET

Bayer, Memiontec, Deutsche Telekom - With blue chips through inflation

  • Technology

When inflation rates started to rise in the USA and Germany, all sides initially said this phenomenon was temporary. In the meantime, it has become clear that the experts were wrong. Inflation has come to stay and brings inflation rates we have not seen for decades. In November, it was 5.2% in Germany. Typically, it would be the ECB's job to control inflation, but its hands are tied because of the interest rate problem. That leaves investors with the question of how best to protect their money. One option is to look at blue chips, three of which we will examine in more detail today.

Read

Commented by André Will-Laudien on December 30th, 2021 | 11:53 CET

Royal Dutch, Saturn Oil + Gas, Bayer: The oil price and the pandemic in 2022

  • Oil

COVID-19 is a black swan for the economy, but does the pandemic favor lower or higher oil prices? Not an easy determination because, for one thing, the measures to contain the pandemic significantly lower economic activity. Production delays and supply chain failures occur, so oil demand should fall there. On the other hand, a shortage of inputs and constraints in logistics lead to higher delivery and waiting times, thus creating some hoarding pressure, which increases demand for the black gold. Due to the shortness of history, the actual connection is also little researched, i.e. how it really is could remain hidden from us for some time. Who benefits from the current cycle of price increases?

Read

Commented by Carsten Mainitz on December 28th, 2021 | 11:26 CET

Novavax, XPhyto Therapeutics, Bayer - Corona shares for 2022!

  • Biotechnology

The head of the Robert Koch Institute, Lothar Wieler, warned a few days ago that the healthcare system would be overburdened and critical care structures impaired if the feared Omicron wave could not be curbed. This situation illustrates that the pandemic is far from letting us go. Vaccine manufacturers and pharmaceutical companies will continue to benefit. Their shares should also be on the winning side next year.

Read

Commented by Stefan Feulner on December 23rd, 2021 | 11:15 CET

Novavax, Sativa Wellness Group, Bayer - The next wave ignites

  • Cannabis

There is great concern in society due to the Omicron variant. Reason enough for politicians to further tighten measures, even for the approximately 70% of fully vaccinated people in the Federal Republic. The federal and state governments decided on stricter contact restrictions, large events without spectators and a new vaccination target. By the end of January, a further 30 million booster, first and second vaccinations are to be achieved. As a result, vaccine manufacturers are experiencing another boom. Meanwhile, a new vaccine is coming to Germany to change the minds of vaccination skeptics.

Read

Commented by Stefan Feulner on December 21st, 2021 | 13:03 CET

BioNTech, Memiontec, Bayer - Catastrophic conditions

  • Technology

There is no question that the Corona pandemic must be fought by all means. Nevertheless, apart from the virus and the question of vaccination, testing and boosters, there are far worse problems on our planet. For example, did you know that in the top daily news, it is reported that some 2.2 billion people have no sustainable, safe and readily available access to drinking water? Or that 361,000 children under the age of five die each year from diarrheal diseases caused by dirty water and contaminated food? The issue of water will be increasingly prominent in the headlines over the next few years. You can already invest in tomorrow's winners.

Read

Commented by Fabian Lorenz on December 14th, 2021 | 12:40 CET

BioNTech, Bayer, Ayurcann: From vaccination records to cannabis

  • Cannabis

The COVID-19 pandemic is dominating the headlines. There is no end in sight to the pandemic. The shares of BioNTech are benefiting from this. The Mainz-based Company has developed the most successful vaccine to date. The blockbuster is likely to remain in demand and generate billions in revenue for BioNTech. Thus, Berenberg sees a price target of USD 400. Health Minister Karl Lauterbach referred to a necessary vaccination rate of over 90% in the ARD program "Anne Will". BioNTech is currently expanding its production capacity. Just like Ayurcann. Because the legalization of cannabis opens the door to a billion-dollar market for the Canadian Company. Bayer also made headlines yesterday - the US Supreme Court is taking a closer look at the glyphosate dispute. That is new food for the gamblers. They have the Bayer share firmly in their grip.

Read

Commented by Stefan Feulner on December 10th, 2021 | 13:54 CET

Bayer, Almonty Industries, JinkoSolar - Still considerable room for improvement

  • Tungsten

Inflation is growing relentlessly. In November, Germany's barometer for price increases climbed to 5.2%; a level last reached 29 years ago. Rising energy prices and exploding commodity prices are found to be the culprits here. Given the energy turnaround, the materials required for this, such as lithium, copper and cobalt, are in fact close to their highs. However, tungsten, which will be essential for electromobility in the future, still has some catching-up potential.

Read